1. Воробьев П.А., Чуланов В.П., Телегина И.В., Борисенко О.В. Анализ воспринимаемой ценности при реализации стратегии лечения больных хроническим гепатитом В препаратом энтекавира. Инфекционные болезни. 2011;9(3):5-12.

2. Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2011;34(10):1145-58. doi: 10.1111/j.1365-2036.2011.04869.x.

3. Dooley JS, Look ASF, Burroughs AK, Heath- cote EJ, editors. Sherlok's diseases of the liver and biliary system. 12 th edition. WILEY-BLACK- WELL; 2011.771 p.

4. Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis. 2006;26(2):130-41.

5. Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology. 2000;31(5):1037-44.

6. Manesis EK. HBeAg-negative chronic hepatitis B: from obscurity to prominence. J Hepatol. 2006;45(3):343-6.

7. Niederau C. Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit. World J Gastroenterol. 2014;20(33):11595-617. doi: 10.3748/wjg.v20.i33.11595.

8. Santantonio TA, Fasano M. Chronic hepatitis B: advances in treatment. World J Hepatol. 2014;6(5):284-92. doi: 10.4254/wjh.v6.i5.284.

9. World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. MARCH 2015. World Health Organization; 2015. 134 p. Available from: www.who. int/about/licensing/copyright_form/en/in- dex.html

10. Zhou Y, Holmes EC. Bayesian estimates of the evolutionary rate and age of hepatitis B virus. J Mol Evol. 2007;65(2):197-205.